Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Expected to Post Quarterly Sales of $31.20 Million

Wall Street brokerages expect that Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) will announce sales of $31.20 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Spectrum Pharmaceuticals’ earnings. The lowest sales estimate is $27.90 million and the highest is $33.10 million. Spectrum Pharmaceuticals posted sales of $33.95 million during the same quarter last year, which suggests a negative year over year growth rate of 8.1%. The company is scheduled to announce its next quarterly earnings report on Tuesday, August 8th.

On average, analysts expect that Spectrum Pharmaceuticals will report full year sales of $31.20 million for the current financial year, with estimates ranging from $111.35 million to $124.50 million. For the next year, analysts forecast that the business will post sales of $125.61 million per share, with estimates ranging from $104.74 million to $139.10 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last released its quarterly earnings results on Tuesday, May 2nd. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.02. The company had revenue of $29.10 million for the quarter, compared to analyst estimates of $32.23 million. Spectrum Pharmaceuticals had a negative return on equity of 24.06% and a negative net margin of 62.39%.

A number of research analysts have commented on the company. Jefferies Group LLC set a $9.00 target price on Spectrum Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, June 8th. Zacks Investment Research upgraded Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 6th. ValuEngine upgraded Spectrum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, May 11th. HC Wainwright set a $10.00 price target on Spectrum Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, May 6th. Finally, FBR & Co reiterated a “buy” rating on shares of Spectrum Pharmaceuticals in a research report on Saturday, April 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Spectrum Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $8.90.

Spectrum Pharmaceuticals (NASDAQ:SPPI) traded up 0.81% on Friday, reaching $7.51. The company’s stock had a trading volume of 283,704 shares. The company’s market capitalization is $589.71 million. The firm’s 50 day moving average price is $6.37 and its 200-day moving average price is $5.90. Spectrum Pharmaceuticals has a 52 week low of $3.21 and a 52 week high of $8.00.

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Spectrum Pharmaceuticals by 13.8% in the first quarter. Vanguard Group Inc. now owns 7,208,723 shares of the biotechnology company’s stock valued at $46,858,000 after buying an additional 874,871 shares in the last quarter. State Street Corp boosted its stake in Spectrum Pharmaceuticals by 45.3% in the first quarter. State Street Corp now owns 2,353,958 shares of the biotechnology company’s stock valued at $15,305,000 after buying an additional 733,651 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Spectrum Pharmaceuticals by 9.7% in the first quarter. Renaissance Technologies LLC now owns 5,679,800 shares of the biotechnology company’s stock valued at $36,919,000 after buying an additional 502,488 shares in the last quarter. Kennedy Capital Management Inc. acquired a new stake in Spectrum Pharmaceuticals during the first quarter valued at approximately $2,054,000. Finally, ClariVest Asset Management LLC acquired a new stake in Spectrum Pharmaceuticals during the first quarter valued at approximately $1,573,000. Hedge funds and other institutional investors own 67.33% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/07/29/spectrum-pharmaceuticals-inc-nasdaqsppi-expected-to-post-quarterly-sales-of-31-20-million-updated-updated-updated.html.

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Get a free copy of the Zacks research report on Spectrum Pharmaceuticals (SPPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply